HRP20170814T4 - Prevencija nuspojava uzrokovanih cd3 specifičnim veznim domenama - Google Patents
Prevencija nuspojava uzrokovanih cd3 specifičnim veznim domenama Download PDFInfo
- Publication number
- HRP20170814T4 HRP20170814T4 HRP20170814TT HRP20170814T HRP20170814T4 HR P20170814 T4 HRP20170814 T4 HR P20170814T4 HR P20170814T T HRP20170814T T HR P20170814TT HR P20170814 T HRP20170814 T HR P20170814T HR P20170814 T4 HRP20170814 T4 HR P20170814T4
- Authority
- HR
- Croatia
- Prior art keywords
- binding domain
- dose
- glucocorticoid
- administered
- use according
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims 3
- 230000002411 adverse Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000009870 specific binding Effects 0.000 title 1
- 239000003862 glucocorticoid Substances 0.000 claims 10
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 206010003062 Apraxia Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 208000007542 Paresis Diseases 0.000 claims 1
- 206010040026 Sensory disturbance Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 208000004209 confusion Diseases 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 206010013395 disorientation Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000027765 speech disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developing Agents For Electrophotography (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Materials For Medical Uses (AREA)
- Steroid Compounds (AREA)
Claims (7)
1. Glukokortikoid (GC) za uporabu u metodi profilakse neuroloških nuspojava uzrokovanih primjenom CD3 vezne domene, pri čemu se GC primijenjuje prije primjene prve doze CD3 vezne domene i prije primjene druge doze i/ili treće doze CD3 vezne domene, pri čemu se prvu dozu CD3 vezne domene primijenjuje u prvom vremenskom razdoblju i slijedom se drugu dozu CD3 vezne domene primijenjuje u drugom vremenskom razdoblju, pri čemu druga doza premašuje prvu dozu, pri čemu je GC deksametazon, pri čemu je navedena neurološka nuspojava jedan ili više poremećaja osjeta, napadaji, encefalopatija, cerebralni edem, konfuzija, ataksija, apraksija, poremećaj govora, pareza, tremor ili disorijentacija, pri čemu je navedena CD3 vezna domena CD19 x CD3 bispecifično jednolančano protutijelo.
2. Glukokortikoid za uporabu u skladu s patentnim zahtjevom 1, pri čemu se nakon prve i druge doze CD3 vezne domene u prvom i drugom vremenskom razdoblju primijenjuje treća doza CD3 vezne domene, pri čemu treća doza premašuje prvu i drugu dozu.
3. Glukokortikoid za uporabu u skladu s patentnim zahtjevom 1, pri čemu se CD3 veznu domenu primijenjuje neprekidno.
4. Glukokortikoid za uporabu u skladu s patentnim zahtjevom 1, pri čemu je navedeno CD19 x CD3 bispecifično jednolančano protutijelo MT103.
5. Glukokortikoid za uporabu u skladu s vilo kojim od prethodnih patentnih zahtjeva, pri čemu je navedeni pacijent čovjek.
6. Glukokortikoid za uporabu u skladu s vilo kojim od prethodnih patentnih zahtjeva, pri čemu je navedeni pacijent naznačen time što ima omjer B/T-stanica manji od 1:5.
7. Glukokortikoid za uporabu u skladu s vilo kojim od patentnih zahtjeva 1 do 6, pri čemu se navedena CD3 vezna domena veže na ljudski CD3 epsilon.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41222910P | 2010-11-10 | 2010-11-10 | |
| PCT/EP2011/068862 WO2012062596A1 (en) | 2010-11-10 | 2011-10-27 | Prevention of adverse effects caused by cd3 specific binding domains |
| EP11788077.3A EP2637670B2 (en) | 2010-11-10 | 2011-10-27 | Prevention of adverse effects caused by cd3 specific binding domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20170814T1 HRP20170814T1 (hr) | 2017-08-11 |
| HRP20170814T4 true HRP20170814T4 (hr) | 2024-05-10 |
Family
ID=45044532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170814TT HRP20170814T4 (hr) | 2010-11-10 | 2011-10-27 | Prevencija nuspojava uzrokovanih cd3 specifičnim veznim domenama |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US10130638B2 (hr) |
| EP (3) | EP3228315B1 (hr) |
| JP (2) | JP6023717B2 (hr) |
| KR (1) | KR101891845B1 (hr) |
| CN (2) | CN103533943B (hr) |
| AU (3) | AU2011328393B2 (hr) |
| CA (1) | CA2816668C (hr) |
| CL (1) | CL2013001287A1 (hr) |
| CR (1) | CR20130278A (hr) |
| CY (1) | CY1118894T1 (hr) |
| DK (1) | DK2637670T4 (hr) |
| EA (1) | EA026075B1 (hr) |
| ES (2) | ES2842937T3 (hr) |
| FI (1) | FI2637670T4 (hr) |
| HR (1) | HRP20170814T4 (hr) |
| HU (1) | HUE032782T2 (hr) |
| IL (2) | IL226268B (hr) |
| LT (1) | LT2637670T (hr) |
| MA (1) | MA34726B1 (hr) |
| ME (1) | ME02722B (hr) |
| MY (1) | MY173177A (hr) |
| NZ (1) | NZ610034A (hr) |
| PL (1) | PL2637670T5 (hr) |
| PT (1) | PT2637670T (hr) |
| RS (1) | RS55995B2 (hr) |
| SG (2) | SG190174A1 (hr) |
| SI (1) | SI2637670T2 (hr) |
| TN (1) | TN2013000250A1 (hr) |
| UA (1) | UA113397C2 (hr) |
| WO (1) | WO2012062596A1 (hr) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1874821T3 (da) | 2005-04-26 | 2013-07-08 | Trion Pharma Gmbh | Kombination af antistoffer med glykokortikoider til behandling af kræft |
| HRP20170814T4 (hr) | 2010-11-10 | 2024-05-10 | Amgen Research (Munich) Gmbh | Prevencija nuspojava uzrokovanih cd3 specifičnim veznim domenama |
| MX354371B (es) * | 2011-04-28 | 2018-02-28 | Amgen Res Munich Gmbh | Régimen de dosificación para administrar un anticuerpo biespecífico cd19xcd3 a pacientes en riesgo de efectos adversos potenciales. |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| EP3620473A1 (en) | 2013-01-14 | 2020-03-11 | Xencor, Inc. | Novel heterodimeric proteins |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| JO3529B1 (ar) * | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
| KR102211176B1 (ko) * | 2013-03-15 | 2021-02-01 | 젠코어 인코포레이티드 | 이형이량체 단백질 |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| AU2014232416B2 (en) | 2013-03-15 | 2017-09-28 | Xencor, Inc. | Modulation of T Cells with Bispecific Antibodies and FC Fusions |
| WO2015095392A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| US9822186B2 (en) | 2014-03-28 | 2017-11-21 | Xencor, Inc. | Bispecific antibodies that bind to CD38 and CD3 |
| EP3693391A1 (en) | 2014-09-12 | 2020-08-12 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| CU24597B1 (es) | 2014-11-26 | 2022-05-11 | Xencor Inc | Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20 |
| TWI713480B (zh) | 2014-12-05 | 2020-12-21 | 美商建南德克公司 | 抗ＣＤ７９ｂ抗體及其使用方法 |
| US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
| WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| FI3310814T3 (fi) | 2015-06-16 | 2023-09-21 | Hoffmann La Roche | HUMANISOITUJA JA AFFINITEETTIKYPSIÄ FcRH5-VASTA-AINEITA JA KÄYTTÖMENETELMIÄ |
| EP3310378B1 (en) | 2015-06-16 | 2024-01-24 | F. Hoffmann-La Roche AG | Anti-cll-1 antibodies and methods of use |
| JP2018524373A (ja) | 2015-07-15 | 2018-08-30 | ザイムワークス，インコーポレイテッド | 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| CN106810610A (zh) * | 2015-11-30 | 2017-06-09 | 中国科学院深圳先进技术研究院 | 抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用 |
| CN106810611A (zh) * | 2015-11-30 | 2017-06-09 | 中国科学院深圳先进技术研究院 | 抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用 |
| US10227410B2 (en) | 2015-12-07 | 2019-03-12 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
| EA039859B1 (ru) * | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| LT3411404T (lt) | 2016-02-03 | 2022-12-27 | Amgen Research (Munich) Gmbh | Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai |
| MA45255A (fr) | 2016-06-14 | 2019-04-17 | Xencor Inc | Anticorps inhibiteurs de points de contrôle bispécifiques |
| RU2019102008A (ru) | 2016-06-28 | 2020-07-28 | Ксенкор, Инк. | Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| KR102649972B1 (ko) | 2016-10-14 | 2024-03-22 | 젠코어 인코포레이티드 | IL15/IL15Rα 이종이량체 Fc-융합 단백질 |
| CN109923128A (zh) | 2016-11-15 | 2019-06-21 | 基因泰克公司 | 用于用抗cd20/抗cd3双特异性抗体进行治疗的给药 |
| US20200078400A1 (en) * | 2016-12-03 | 2020-03-12 | Juno Therapeutics, Inc. | Methods for determining car-t cells dosing |
| KR20180090600A (ko) | 2017-02-03 | 2018-08-13 | 주식회사 대유위니아 | 전기밥솥 |
| EP3409322A1 (en) * | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| WO2019006472A1 (en) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
| CN111051534A (zh) * | 2017-08-30 | 2020-04-21 | 百时美施贵宝公司 | 监测体内施用糖皮质激素介导的药效学反应的方法 |
| WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| CN112272563A (zh) | 2017-11-08 | 2021-01-26 | Xencor股份有限公司 | 使用新颖抗pd-1序列的双特异性和单特异性抗体 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| AU2018390418B2 (en) | 2017-12-19 | 2023-12-21 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
| JP7475275B2 (ja) | 2018-02-08 | 2024-04-26 | ジェネンテック， インコーポレイテッド | 二重特異性抗原結合分子及びその使用方法 |
| EP3773911A2 (en) | 2018-04-04 | 2021-02-17 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| AU2019256529A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains |
| WO2019204665A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| SG11202103192RA (en) | 2018-10-03 | 2021-04-29 | Xencor Inc | Il-12 heterodimeric fc-fusion proteins |
| EP3930850A1 (en) | 2019-03-01 | 2022-01-05 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| RU2738802C1 (ru) * | 2019-08-21 | 2020-12-17 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула |
| US11845799B2 (en) | 2019-12-13 | 2023-12-19 | Genentech, Inc. | Anti-Ly6G6D antibodies and methods of use |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| AU2021287998A1 (en) | 2020-06-11 | 2023-02-02 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| KR20230166150A (ko) | 2020-08-19 | 2023-12-06 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
| IL305736A (en) | 2021-03-09 | 2023-11-01 | Xencor Inc | Heterodimeric antibodies that bind CD3 and CLDN6 |
| WO2022192586A1 (en) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| WO2023057650A1 (en) | 2021-10-10 | 2023-04-13 | Centre Hospitalier Universitaire Vaudois (Chuv) | A method for predicting side effects of drugs and vaccines |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| DE69909459T2 (de) * | 1998-04-21 | 2004-05-27 | Micromet Ag | Cd19xcd3 spezifische polypeptide und deren verwendung |
| US20070224191A1 (en) † | 2002-12-05 | 2007-09-27 | Pdl Biopharma, Inc. | Methods of treatment of Ulcerative Colitis and Crohn's disease with anti-CD3 antibodies |
| AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| DK1874821T3 (da) † | 2005-04-26 | 2013-07-08 | Trion Pharma Gmbh | Kombination af antistoffer med glykokortikoider til behandling af kræft |
| CN101331151A (zh) | 2005-12-16 | 2008-12-24 | 麦克罗梅特股份公司 | ***性疾病的方式和方法 |
| SI1976886T1 (sl) | 2005-12-16 | 2015-03-31 | Amgen Research (Munich) Gmbh | Sredstva in postopki za zdravljenje tumorskih bolezni |
| PL2155788T3 (pl) | 2007-04-03 | 2013-02-28 | Amgen Res Munich Gmbh | Swoiste międzygatunkowe bispecyficzne czynniki wiążące |
| KR101589759B1 (ko) | 2007-04-03 | 2016-01-29 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 ｃｄ３―입실론 결합 도메인 |
| RS58217B1 (sr) | 2007-04-03 | 2019-03-29 | Amgen Res Munich Gmbh | Interspecijski specifičan vezujući domen |
| JP5490714B2 (ja) | 2007-11-28 | 2014-05-14 | メディミューン，エルエルシー | タンパク質製剤 |
| RS54456B1 (en) * | 2008-11-07 | 2016-06-30 | Amgen Research (Munich) Gmbh | TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA |
| SI2493503T2 (sl) * | 2009-10-27 | 2021-04-30 | Amgen Research (Munich) Gmbh | Režim odmerjanja za dajanje cd19xcd3 bispecifičnega protitelesa |
| PT3018145T (pt) | 2010-10-27 | 2018-05-17 | Amgen Res Munich Gmbh | Meios e métodos para tratar o dlbcl |
| HRP20170814T4 (hr) | 2010-11-10 | 2024-05-10 | Amgen Research (Munich) Gmbh | Prevencija nuspojava uzrokovanih cd3 specifičnim veznim domenama |
-
2011
- 2011-10-27 HR HRP20170814TT patent/HRP20170814T4/hr unknown
- 2011-10-27 EP EP17159560.6A patent/EP3228315B1/en active Active
- 2011-10-27 UA UAA201307130A patent/UA113397C2/uk unknown
- 2011-10-27 LT LTEP11788077.3T patent/LT2637670T/lt unknown
- 2011-10-27 JP JP2013538125A patent/JP6023717B2/ja active Active
- 2011-10-27 US US13/884,497 patent/US10130638B2/en active Active
- 2011-10-27 MY MYPI2013001611A patent/MY173177A/en unknown
- 2011-10-27 CN CN201180064622.5A patent/CN103533943B/zh active Active
- 2011-10-27 CA CA2816668A patent/CA2816668C/en active Active
- 2011-10-27 FI FIEP11788077.3T patent/FI2637670T4/fi active
- 2011-10-27 ES ES17159560T patent/ES2842937T3/es active Active
- 2011-10-27 DK DK11788077.3T patent/DK2637670T4/da active
- 2011-10-27 SG SG2013034731A patent/SG190174A1/en unknown
- 2011-10-27 KR KR1020137014669A patent/KR101891845B1/ko active IP Right Grant
- 2011-10-27 PL PL11788077.3T patent/PL2637670T5/pl unknown
- 2011-10-27 EA EA201390621A patent/EA026075B1/ru not_active IP Right Cessation
- 2011-10-27 HU HUE11788077A patent/HUE032782T2/en unknown
- 2011-10-27 EP EP20209362.1A patent/EP3831386A1/en active Pending
- 2011-10-27 SG SG10201508789TA patent/SG10201508789TA/en unknown
- 2011-10-27 PT PT117880773T patent/PT2637670T/pt unknown
- 2011-10-27 ES ES11788077.3T patent/ES2627538T3/es active Active
- 2011-10-27 AU AU2011328393A patent/AU2011328393B2/en active Active
- 2011-10-27 SI SI201131196T patent/SI2637670T2/sl unknown
- 2011-10-27 ME MEP-2017-104A patent/ME02722B/me unknown
- 2011-10-27 WO PCT/EP2011/068862 patent/WO2012062596A1/en active Application Filing
- 2011-10-27 RS RS20170458A patent/RS55995B2/sr unknown
- 2011-10-27 EP EP11788077.3A patent/EP2637670B2/en active Active
- 2011-10-27 NZ NZ610034A patent/NZ610034A/en unknown
- 2011-10-27 CN CN201810044039.1A patent/CN108403702A/zh active Pending
-
2013
- 2013-05-09 CL CL2013001287A patent/CL2013001287A1/es unknown
- 2013-05-09 IL IL226268A patent/IL226268B/en active IP Right Grant
- 2013-06-10 CR CR20130278A patent/CR20130278A/es unknown
- 2013-06-10 TN TNP2013000250A patent/TN2013000250A1/fr unknown
- 2013-06-10 MA MA35999A patent/MA34726B1/fr unknown
-
2016
- 2016-07-06 JP JP2016133918A patent/JP6189491B2/ja active Active
-
2017
- 2017-03-29 AU AU2017202079A patent/AU2017202079B2/en active Active
- 2017-05-08 CY CY20171100491T patent/CY1118894T1/el unknown
-
2018
- 2018-01-25 IL IL257164A patent/IL257164B/en active IP Right Grant
- 2018-02-07 AU AU2018200915A patent/AU2018200915B2/en active Active
- 2018-10-11 US US16/157,985 patent/US11633408B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170814T4 (hr) | Prevencija nuspojava uzrokovanih cd3 specifičnim veznim domenama | |
| HRP20210902T1 (hr) | Postupci pojačavanja tonične inhibicije i liječenja angelmanovog sindroma | |
| JP2016193932A5 (hr) | ||
| HRP20180301T1 (hr) | Postupci liječenja psorijaze uporabom il-17 antagonista | |
| HRP20161284T1 (hr) | METODE LIJEČENJA MULTIPLOG MIJELOMA KORIŠTENJEM KOMBINIRANIH TERAPIJA TEMELJENIH NA HuLuc63 S BORTEZOMIBOM | |
| HRP20201627T1 (hr) | Postupak liječenja s tradipitantom | |
| NZ700881A (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| BR112014028017A2 (pt) | composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror | |
| BR112015018438A2 (pt) | anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento | |
| NZ744567A (en) | Treatment of cancers using pi3 kinase isoform modulators | |
| MY184241A (en) | Human antibodies to gfr?3 and methods of use thereof | |
| AR066916A1 (es) | Anticuerpos conra c3b y metodos para la prevenc ion y el tratamiento de trastornos asociados con el complemento. composicion farmaceutica. | |
| NZ716977A (en) | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of acute and sub-acute cough, urge to cough and chronic cough, in respiratory diseases | |
| MTP4289B (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
| BR112014010803A2 (pt) | método de tratamento | |
| WO2015038939A3 (en) | Modulators of complement factor b | |
| BR112014003704A2 (pt) | moduladores ror gama | |
| MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
| JOP20170091B1 (ar) | إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية | |
| FR2994386B1 (fr) | Inhibition de l'adhesion de micro-organismes pathogenes par un ester de saccharose et/ou de sorbitan dans le traitement cosmetique de l'atopie cutanee | |
| AR092103A1 (es) | Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1) | |
| MY171048A (en) | Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions | |
| EP4230197A3 (en) | High concentration medicant solutions for treating neurological disorders | |
| MX2015016062A (es) | Sub-poblacion de monocitos humanos para el tratamiento de enfermedades y trastornos del ojo. |